Opus Genetics Inc (IRD)

$0.94 -0.03 (-2.96%)
Market Cap 57.87M
Revenue (ttm) 10.99M
Net Income (ttm) -57.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -523.48%
Debt to Equity Ratio 0.00
Volume 223,500
Avg Vol 1,058,794
Day's Range N/A - N/A
Shares Out 59.66M
Stochastic %K 10%
Beta 0.00
Analysts Strong Sell
Price Target $9.25

Company Profile

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal do...

Industry: Biotechnology
Sector: Healthcare
Phone: 984 884 6030
Website: opusgtx.com
Address:
8 Davis Drive, Suite 220, Durham, United States
Maynard_Keysian
Maynard_Keysian Jun. 16 at 5:15 PM
$IRD VEGA-3, Soon
0 · Reply
DGains
DGains Jun. 11 at 3:22 PM
$NXTT Waking UP! 🌅🌻 $RYCEY Chillin’ @ .86 avg 💹 $TSLA TOO EASY !! 🏎️🍿 $IRD Sooon?! 🛫
0 · Reply
JoeD32
JoeD32 Jun. 10 at 3:09 PM
$IRD 💩💩💩
0 · Reply
DGains
DGains Jun. 9 at 8:58 PM
$KLTO LMAO 😂 I said Soon?! @ .19 when no one gave a F?? Now $2.14 💵 $RYCEY TOO EASY 🏎️ $CURR What UP ? 😍 $IRD When? 🌕
0 · Reply
Txybd
Txybd Jun. 9 at 7:57 PM
$IRD let’s gooo!
0 · Reply
Pdowling81
Pdowling81 Jun. 9 at 2:15 PM
$IRD
0 · Reply
Maynard_Keysian
Maynard_Keysian Jun. 6 at 3:07 PM
$IRD It does feel like it has been coiling and about ready to spring.
0 · Reply
rayankhader
rayankhader Jun. 6 at 3:05 PM
$IRD wait until the buyers step in and see where this going 🌕
0 · Reply
TruthTooPower
TruthTooPower Jun. 6 at 2:29 PM
$HOOD !!! $IRD !!! $TRAW !!! $TGL !!! All 4 Retro Rockets Engage!!!
1 · Reply
MrProfits5594
MrProfits5594 Jun. 5 at 7:49 PM
$IRD
0 · Reply
Latest News on IRD
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 14 days ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 4 weeks ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 12, 2025, 8:00 AM EDT - 5 weeks ago

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 6, 2025, 8:00 AM EDT - 5 weeks ago

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

May 5, 2025, 8:00 AM EDT - 6 weeks ago

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Apr 11, 2025, 3:47 PM EDT - 2 months ago

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 8, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Opus Genetics to Participate in Upcoming Investor Conference in April

Apr 2, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Opus Genetics Announces Financial Results for Full Year 2024

Mar 31, 2025, 8:20 AM EDT - 2 months ago

Opus Genetics Announces Financial Results for Full Year 2024

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Mar 21, 2025, 5:03 PM EDT - 3 months ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Mar 21, 2025, 9:30 AM EDT - 3 months ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Mar 21, 2025, 9:11 AM EDT - 3 months ago

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 19, 2025, 3:56 PM EDT - 3 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Mar 5, 2025, 8:00 AM EST - 3 months ago

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Feb 26, 2025, 8:00 AM EST - 3 months ago

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Feb 18, 2025, 7:30 AM EST - 4 months ago

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

Feb 7, 2025, 9:15 AM EST - 4 months ago

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

XBI

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Dec 19, 2024, 8:00 AM EST - 6 months ago

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Maynard_Keysian
Maynard_Keysian Jun. 16 at 5:15 PM
$IRD VEGA-3, Soon
0 · Reply
DGains
DGains Jun. 11 at 3:22 PM
$NXTT Waking UP! 🌅🌻 $RYCEY Chillin’ @ .86 avg 💹 $TSLA TOO EASY !! 🏎️🍿 $IRD Sooon?! 🛫
0 · Reply
JoeD32
JoeD32 Jun. 10 at 3:09 PM
$IRD 💩💩💩
0 · Reply
DGains
DGains Jun. 9 at 8:58 PM
$KLTO LMAO 😂 I said Soon?! @ .19 when no one gave a F?? Now $2.14 💵 $RYCEY TOO EASY 🏎️ $CURR What UP ? 😍 $IRD When? 🌕
0 · Reply
Txybd
Txybd Jun. 9 at 7:57 PM
$IRD let’s gooo!
0 · Reply
Pdowling81
Pdowling81 Jun. 9 at 2:15 PM
$IRD
0 · Reply
Maynard_Keysian
Maynard_Keysian Jun. 6 at 3:07 PM
$IRD It does feel like it has been coiling and about ready to spring.
0 · Reply
rayankhader
rayankhader Jun. 6 at 3:05 PM
$IRD wait until the buyers step in and see where this going 🌕
0 · Reply
TruthTooPower
TruthTooPower Jun. 6 at 2:29 PM
$HOOD !!! $IRD !!! $TRAW !!! $TGL !!! All 4 Retro Rockets Engage!!!
1 · Reply
MrProfits5594
MrProfits5594 Jun. 5 at 7:49 PM
$IRD
0 · Reply
rayankhader
rayankhader Jun. 5 at 3:21 PM
$IRD did you buy the dip
1 · Reply
RCO234
RCO234 Jun. 5 at 6:20 AM
$IRD .66 short interest rate according to fintel. With a hypothetical fast track to market any chance for a short squeeze?
0 · Reply
StockTone
StockTone Jun. 4 at 4:06 PM
$IRD Looking good, trying to pop... 🚀🚀🚀
2 · Reply
rayankhader
rayankhader Jun. 4 at 3:19 PM
$IRD scaling
1 · Reply
ChloeCash
ChloeCash Jun. 4 at 12:07 PM
$IRD please let me get out of this PLEASE IT HAS BEEN YEARS OMG
0 · Reply
TickrTalk0007
TickrTalk0007 Jun. 4 at 3:00 AM
$IRD the data is meaningless…6% difference on low low end of the responders….worse than cancer drugs no mention of this by viatris 😂 tells all you need to know. lot of misinformation in the PR. this mgmt is dud…how much are they spending a qtr again?
2 · Reply
t_baggin_u
t_baggin_u Jun. 3 at 7:05 PM
$IRD !1!
0 · Reply
TruthTooPower
TruthTooPower Jun. 3 at 6:59 PM
$IRD $TRAW !!! Load Em Up!!!
0 · Reply
TruthTooPower
TruthTooPower Jun. 3 at 5:59 PM
$IRD !!! lol… We Will! We Will Rock You!!!
0 · Reply
Atime2Buy
Atime2Buy Jun. 3 at 5:50 PM
$IRD oh wow, we got the Vampire teeth! ……. you know what this means , right?
1 · Reply
GladEator
GladEator Jun. 3 at 5:32 PM
$IRD Garbage Management led us here....
0 · Reply
MrProfits5594
MrProfits5594 Jun. 3 at 5:21 PM
$IRD $2 HERE WE COME !!!
1 · Reply